Clinical trial
Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia…
NCT00397189 · Neurim Pharmaceuticals Ltd., Industry · Completed
Key facts
| NCT number | NCT00397189 |
|---|---|
| Title | Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients |
| Official title | A Double-blind, Parallel Group, Randomised, Placebo Controlled Study of Efficacy and Safety of Circadin® 2 mg in the Treatment of Insomnia Patients With Low Endogenous Melatonin |
| Lead sponsor | Neurim Pharmaceuticals Ltd., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Insomnia |
| Intervention type | Drug |
| Interventions | Circadin, placebo circadin |
| Enrollment | 930 |
| Start date | Oct 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Apr 1, 2009 |
| First posted | Nov 8, 2006 |
| Last update posted | May 1, 2018 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: